CDX genes are classically known as regulators of axial elongation during early embryogenesis. An unsuspected role for CDX genes have been revealed during hematopoietic development. The CDX gene family member CDX2belongs to the most frequent aberrantly expressed proto-oncogenes in human acute leukemias and is highly leukemogenic in experimental models. We used semiquantitative reversed transcriptase polymerase chain reaction (RT-PCR) to determine the expression level of CDX2 gene in 30 pediateric patients with acute lymphoblastic leukemia (ALL) and 30 age and sex matched healthy volunteers. ALL patients were followed up to detect minimal residual disease (MRD) on days 15 and 42 of induction. We found that CDX2 gene was expressed in 50% of patients and not expressed in controls. Correlations between gene expression and different clinical and laboratory data of patients revealed no impact on different data. With follow up, we could not confirm that CDX2 expression had a prognostic significance.